---
document_datetime: 2024-12-06 14:02:13
document_pages: 41
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/votubia-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf
document_name: votubia-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf
version: success
processing_time: 36.0220066
conversion_datetime: 2025-12-27 09:51:31.367959
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Votubia

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IAIN/0090            | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 04/12/2024                          |                                             | Annex II and PL                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| PSUSA/1343/ 202403   | Periodic Safety Update EU Single assessment - everolimus (indicated for astrocytoma (SEGA), renal angiomyolipoma, refractory seizures)                                                                                                                                                                                                                                                                                                                             | 28/11/2024   | n/a   | PRAC Recommendation - maintenance   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------------------------------|
| II/0089              | Submission of the final report from study CRAD001M2305 listed as a category 3 study in the RMP. This is an interventional PASS study to monitor the growth and development of paediatric patients previously treated with everolimus in study CRAD001M2301 (EXIST-LT). The RMP version 16.0 has also been submitted. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 05/09/2024   | n/a   | Not applicable                      |
| IG/1758              | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                      | 12/06/2024   | n/a   |                                     |
| IG/1724/G            | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                | 26/03/2024   | n/a   |                                     |
| IB/0085              | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                         | 26/10/2023   | n/a   |                                     |
| IB/0083/G            | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                 | 20/09/2023   | n/a   |                                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.II.b.4.z - Change in the batch size (including batch size ranges) of the finished product - Other variation B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch   |            |     |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0084/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 17/08/2023 | n/a |

<div style=\"page-break-after: always\"></div>

|           | for batch release) A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                 |            |     | (excluding manufacturer   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------|
| IB/0082/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 28/07/2023 | n/a |                           |
| WS/2472   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                | 01/06/2023 | n/a |                           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0080/G   | This was an application for a group of variations. B.II.b.4.z - Change in the batch size (including batch size ranges) of the finished product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place   | 18/11/2022   | n/a   |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| IB/0079     | B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 29/07/2022   | n/a   |

<div style=\"page-break-after: always\"></div>

| IG/1520            | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                  | 24/06/2022   | 19/06/2023   | SmPC        |                                   |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|-----------------------------------|
| IG/1518            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                 | 24/06/2022   | 19/06/2023   | SmPC and PL |                                   |
| IG/1521            | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                             | 23/06/2022   | n/a          |             |                                   |
| PSUSA/1343/ 202103 | Periodic Safety Update EU Single assessment - everolimus (indicated for astrocytoma (SEGA), renal angiomyolipoma, refractory seizures)                                                                                                                                                                                                                                                                                         | 02/12/2021   | n/a          |             | PRAC Recommendation - maintenance |
| IA/0075/G          | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place | 23/11/2021   | n/a          |             |                                   |
| N/0073             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                               | 12/10/2021   | 21/06/2022   | PL          |                                   |
| IA/0074            | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect                                                                                                                                                                                                                                                                         | 10/09/2021   | n/a          |             |                                   |

<div style=\"page-break-after: always\"></div>

|             | the product information                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                                  |                                                                                                                                                                                                                                                                                                                                        |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/2110/G   | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation A.7 - Administrative change - Deletion of manufacturing sites | 02/09/2021 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                        |
| IAIN/0070/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                        | 03/06/2021 | 21/06/2022 | Annex II and PL                  |                                                                                                                                                                                                                                                                                                                                        |
| WS/1995     | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of the Afinitor and Votubia SmPCs to include radiation recall syndrome as an adverse drug reaction observed in the post-marketing phase with                                                                                                              | 20/05/2021 | 21/06/2022 | SmPC, Annex II, Labelling and PL | SmPC new text Radiation therapy complications Serious and severe radiation reactions (such as radiation oesophagitis, radiation pneumonitis and radiation skin injury), including fatal cases, have been reported when everolimus was taken during, or shortly after, radiation therapy. Caution should therefore be exercised for the |

<div style=\"page-break-after: always\"></div>

|           | unknown frequency (Section 4.8) and a cautionary text regarding radiation therpay complications in 'Special warnings and precautions for use' (Section 4.4). Corresponding changes are also made to the SmPC section 4.5 and package leaflets. Taking the opportunity, the MAH also proposed some editorial changes to harmonize the information in Afinitor and Votubia SmPC (Sections 4.7 and 4.8) and Package leaflet 'Afinitor with food and drink.' Afinitor PI is further updated in compliance with the QRD template version 10.1, while Votubia PI was already updated within the procedure II/061. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |     | potentiation of radiotherapy toxicity in patients taking everolimus in close temporal relationship with radiation therapy. Additionally, radiation recall syndrome (RRS) has been reported in patients taking everolimus who had received radiation therapy in the past. In the event of RRS, interrupting or stopping everolimus treatment should be considered. For more information, please refer to the Summary of Product Characteristics.   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0069/G | This was an application for a group of variations. B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished                                                                                             | 08/01/2021 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| product - Minor changes procedure B.II.d.2.a - Change in product - Minor changes procedure B.II.d.2.a - Change in product - Minor changes procedure B.II.b.3.a - Change in the finished or intermediate in the manufacturing process B.II.b.3.a - Change in the finished or intermediate in the manufacturing process B.II.b.3.a - Change in the finished or intermediate in the manufacturing process B.II.b.3.a - Change in the finished or intermediate in the manufacturing process B.II.b.3.a - Change in the finished or intermediate in the manufacturing process B.II.b.3.a - Change in the finished or intermediate in the manufacturing process B.II.b.3.a - Change in the finished or intermediate in the manufacturing process B.II.b.3.a - Change in the finished or intermediate   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.z - Change to importer, batch release arrangements and quality control testing of the FP - Other variation B.II.b.2.z - Change to importer, batch release arrangements and quality control testing of the FP - Other variation B.II.b.2.z - Change to importer, batch release arrangements and quality control testing of the FP - Other variation B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary   |            |     |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| WS/1923 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 29/10/2020 | n/a |

<div style=\"page-break-after: always\"></div>

|           | Submission of the Final Clinical Study Report for study CRAD001MIC03 (TOSCA), an international disease registry collecting data on manifestations, interventions and outcomes in patients with tuberous sclerosis complex (TSC), for Votubia. The RMP version 15.0 is submitted to reflect the completion of MEA 14.4 (Votubia) and to remove important safety concerns as recommended by the PRAC (EMEA/H/C/WS1671). C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority   |            |            |                                  |                                                                                  |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------|
| II/0061   | Update of sections 4.2, 5.1, and 5.2 of the SmPC based on results from a modelling and simulation study of patients from 6 months to less than 2 years of age whose refractory partial-onset seizures, with or without secondary generalisation, are associated with tuberous sclerosis complex. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.1. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                          | 23/07/2020 | 25/08/2020 | SmPC, Annex II, Labelling and PL | Please refer to Scientific Discussion 'Product Name-H-C- Product Number-II-0061' |
| R/0065    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 28/05/2020 | 23/07/2020 | PL                               |                                                                                  |
| IB/0066/G | This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 26/06/2020 | n/a        |                                  |                                                                                  |

<div style=\"page-break-after: always\"></div>

|             | finished or intermediate product - Other variation - Stability of FP - Change in the shelf-life or conditions of the finished product - Other                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |                 | the B.II.f.1.z storage variation   |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|------------------------------------|
| WS/1777     | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.III.2.a.1 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 26/03/2020 | n/a        |                 | a Member State -                   |
| IAIN/0064/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 22/01/2020 | 23/07/2020 | Annex II and PL |                                    |

<div style=\"page-break-after: always\"></div>

| A.5.b - Administrative change and/or address of a manufacturer/importer finished product, including (excluding manufacturer A.5.b - Administrative change and/or address of a manufacturer/importer finished product, including (excluding manufacturer A.5.b - Administrative change and/or address of a manufacturer/importer finished product, including (excluding manufacturer A.5.b - Administrative change and/or address of a manufacturer/importer finished product, including (excluding manufacturer A.7 - Administrative change manufacturing sites A.7 - Administrative change manufacturing sites A.7 - Administrative change manufacturing sites A.7 - Administrative change manufacturing sites B.II.b.1.a - Replacement manufacturing site for the site B.II.b.1.a - Replacement manufacturing site for the site B.II.b.1.a - Replacement   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing   |            |     | site   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------|
| IB/0062/G | This was an application for a group of variations. B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                              | 22/11/2019 | n/a |        |
| WS/1671   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 03/10/2019 | n/a |        |

<div style=\"page-break-after: always\"></div>

|           | To update the RMP for Afinitor and Votubia to version 14.0 to change the safety concerns, to reflect the completion of pharmacovigilance studies [CRAD001Y2201 (Afinitor II/0058), CRAD001M2304 (Votubia II/0051), CRAD001J2301 (Afinitor II/0051/G), CRAD00W2301 (Afinitor II/0051/G)] and to implement the latest GVP module V rev.2 template; the change has been agreed by the PRAC in the outcome of a PSUR assessment (EMEA/H/C/PSUSA/00010268/201703). C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH significant assessment is required   |            |     | where   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------|
| IG/1135/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                                                                                                    | 30/08/2019 | n/a |         |

<div style=\"page-break-after: always\"></div>

| IG/1100            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 24/05/2019   | n/a   |                                   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| IG/1099            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 24/05/2019   | n/a   |                                   |
| PSUSA/1343/ 201803 | Periodic Safety Update EU Single assessment - everolimus (indicated for astrocytoma (SEGA), renal angiomyolipoma, refractory seizures)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 31/10/2018   | n/a   | PRAC Recommendation - maintenance |
| WS/1324/G          | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a | 13/09/2018   | n/a   |                                   |

<div style=\"page-break-after: always\"></div>

|         | Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.c.1.z - Change in immediate packaging of the AS   |            |     |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| II/0055 | Submission of the final report from the non- interventional study CRAD001MIC03, listed as a category 3 study in the RMP. This is an international disease registry collecting data on manifestations, interventions and outcomes in patients with tuberous sclerosis complex. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 06/09/2018 | n/a |

<div style=\"page-break-after: always\"></div>

| II/0051     | Update of sections 4.8 (all pharmaceutical forms)                                                                                                                                                                                                                                                                                                 | 12/07/2018   | 12/06/2019   | SmPC and PL   |      |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|------|
| IAIN/0056/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging | 10/07/2018   | n/a          |               | site |
| IG/0950     | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                  | 18/06/2018   | n/a          |               |      |

<div style=\"page-break-after: always\"></div>

|           | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                   | 16/05/2018   | 07/06/2018   | SmPC, Labelling and PL   | T/0052                 |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|------------------------|
| X/0045    | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                            | 22/03/2018   | 31/05/2018   | SmPC, Labelling and PL   |                        |
| IB/0048/G | This was an application for a group of variations. B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation               | 05/01/2018   | n/a          |                          |                        |
| IB/0049   | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                                            | 20/11/2017   | n/a          |                          |                        |
|           | This was an application for a group of variations. B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product | 16/10/2017   | 31/05/2018   | SmPC, Labelling and PL   | IB/0047/G              |
| IG/0829   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder starting material, reagent or                                                                                                                                                                                     | 18/08/2017   | n/a          |                          | or supplier of the AS, |

<div style=\"page-break-after: always\"></div>

|         | intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0044 | Update of sections 4.2, 4.4 and 4.8 of the SmPC for Votubia 2.5 mg, 5 mg and 10 mg tablets and 2 mg, 3 mg and 5 mg dispersible tablets in order to reflect on data from study CRAD001M2304, in particular to revise dosing recommendations for patients with hepatic impairment, to update the warning related to infections, to include 'sepsis' as an adverse drug reaction with the frequency 'uncommon' and to revise frequencies of the following adverse drug reactions: 'pharyngitis' ['common' to 'very common'], 'pneumonitis' ['uncommon' to 'common'] and 'rash' ['common' to 'very common]'. In addition, the subsection on Paediatric population in section 4.8 of the SmPC was updated based on results from study CRAD001M2304. Furthermore, sections 5.1 and 5.2 of the SmPC for Votubia 2 mg, 3 mg and 5 mg dispersible tablets was updated to add new information on pharmacodynamic and pharmacokinetic properties based on results from study CRAD001M2304. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 22/06/2017 | 26/07/2017 | SmPC and PL | Based on the results from study CRAD001M2304, the CHMP considered that dose adjustments should be recommended in patients 18 years of age with hepatic impairment. In particular, in patients with moderate hepatic impairment (Child Pugh B): 50% of the recommended starting dose calculated based on BSA should be administered. In patients with severe hepatic impairment (Child Pugh C), Votubia is only recommended if the desired benefit outweighs the risk. In this case, 25% of the dose calculated based on BSA must not be exceeded. Some infections affecting patients treated with Votubia were severe, e.g. leading to sepsis, including septic shock. The CHMP considered that this information should be highlighted in the Product Information as a warning and signs of serious infections (fever, chills, rapid breathing and heart rate, rash, and possibly confusion and disorientation) should be presented in the Package Leaflet. Frequency of other adverse drug reactions (pharyngitis, pneumonitis and rash) was also updated based on the available study data. With regards to clinical efficacy, reduction in seizure frequency was sustained over an evaluation period of approximately 2 years. Based on a sensitivity analysis considering patients who prematurely discontinued Votubia as non-responders, response rates of 38.8% and 41.0% were observed at Week 54 and Week 102, respectively. Minor amendments were introduced with regards to information on pharmacokinetics based on the study results. |

<div style=\"page-break-after: always\"></div>

| WS/1144/G   | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.4 and 5.1 of the SmPC in order to include new safety information on stomatitis and its management based on final results from study CRAD001JUS226: a phase II, single arm study of the use of steroid-based mouthwash to prevent stomatitis in postmenopausal women with advanced or metastatic hormone receptor positive breast cancer being treated with everolimus plus exemestane Update of section 4.6 of the SmPC in order to add new information on breast-feeding based on pre- clinical data. The Package Leaflets were updated accordingly. In addition, the Worksharing applicant (WSA) took the opportunity to bring the Afinitor PI in line with the latest QRD template version 10. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   | 29/06/2017   | 31/05/2018   | SmPC, Labelling and PL   | Results from a single-arm study in postmenopausal breast cancer patients treated with everolimus plus exemestane suggested that an alcohol-free corticosteroid oral solution, administered as a mouthwash during the initial 8 weeks of treatment when stomatitis mostly occurs, may decrease the incidence and severity of stomatitis. Management of stomatitis may therefore include prophylactic and/or therapeutic use of topical treatments, such as an alcohol- free corticosteroid oral solution as a mouthwash. Furthermore, monitoring for and treatment of fungal infection was recommended, especially in patients being treated with steroid-based medications. The overall safety profile in this study was consistent with that established for everolimus in the oncology and tuberous sclerosis complex settings, with the exception of a slightly increased frequency of oral candidiasis. Based on pre-clinical data suggesting a potential risk of excretion of everolimus in breast milk and considering its elimination half-life, women taking everolimus should not breastfeed during treatment and for 2 weeks after the last dose.   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/1160     | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 18/05/2017   | 31/05/2018   | Annex II                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|         | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0041 | Extension of Indication to include adjunctive treatment of patients aged 2 years and older with refractory seizures associated with tuberous sclerosis complex (TSC) for Votubia 2 mg, 3 mg and 5 mg dispersible tablets. Sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC were updated in parallel based on the results from the pivotal study. In addition, sections 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 were also updated for the 2.5 mg, 5 mg and 10 mg tablets to reflect on data relevant to these formulations. The Package Leaflet was updated in accordance. Furthermore, the PI was brought in line with the latest QRD template version 10. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or | 15/12/2016 | 27/01/2017 | SmPC, Labelling and PL           | Please refer to the Scientific Discussion Votubia EMEA/H/C/002311/II/0041.                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0039 | Update of sections 4.2 and 4.8 (for dispersible tablets) and sections 4.2, 4.8 and 5.1 (for tablets) of the SmPC in order to update the safety and efficacy information with the data from the final CSR comprising the extension phase of study M2302 in fulfilment of PAM (ANX 027). The Annex II and Package Leaflet are updated accordingly. In addition, the Marketing authorisation holder (MAH) took the                                                                                                                                                                                                                                                                                                                                            | 25/02/2016 | 27/01/2017 | SmPC, Annex II, Labelling and PL | In the pivotal study conducted to evaluate the efficacy and safety of Votubia in patients with TSC plus renal angiomyolipoma, patients initially treated with placebo were allowed to cross over to everolimus at the time of angiomyolipoma progression and upon recognition that treatment with everolimus was superior to treatment with placebo. At the time of the final analysis (4 years following the last patient randomisation), the median duration of |

<div style=\"page-break-after: always\"></div>

|         | opportunity to make minor editorial changes in the SmPC and to make few updates in the PI in order to align with Afinitor PI. Furthermore, the MAH took the opportunity to bring the PI in line with the latest QRD template version 9.1. Moreover, the revised RMP version 11.0 has been submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |                       | exposure to everolimus was 204.1 weeks (range 2 to 278). The angiomyolipoma best overall response rate had increased to 58.0% (95% CI: 48.3, 67.3), with a rate of stable disease of 30.4%. Similar improvements were seen in terms of reduction in angiomyolipoma volume, median time to angiomyolipoma progression, skin lesion response rate and SEGA response rate (based on an exploratory analysis in patients who also had SEGA). Among patients treated with everolimus during the study, no cases of angiomyolipoma-related nephrectomy and only one case of renal embolisation were reported. For more information, please refer to the Summary of Product Characteristics.   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0040 | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                               | 10/12/2015 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| II/0038 | Update of sections 4.2 and 5.2 of the SmPC in order to define an appropriate initial dose for patients below the age of 3 years following requested additional simulations and Literature searches analysis. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                               | 22/10/2015 | 10/12/2015 | SmPC and PL           | The recommended starting dose for Votubia for the treatment of patients with SEGA is 4.5 mg/m2. A higher starting dose of 7 mg/m2 is recommended for patients 1 to less than 3 years of age based on pharmacokinetic simulations.                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0034 | Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to update product information after completion of long-term follow up on duration of responses and                                                                                                                                                                                                                                                              | 24/09/2015 | 16/11/2015 | SmPC, Annex II and PL | Clinical study results did not show an impact of Votubia on growth and pubertal development. The long-term follow-up of patients randomised to everolimus and patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|                    | time to progression for study M2301. The Package Leaflet is updated accordingly. The data submitted fulfils the specific obligation SOB 024 and the Conditional Marketing Authorisation is switched to a Marketing Authorisation not subject to specific obligations. Votubia is also removed from the European list of additionally monitored medicines. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            | randomised to placebo who thereafter crossed over to everolimus demonstrated durable responses. The most frequent adverse reactions (incidence 1/10 and suspected by the investigator to be related to treatment) from the pooled safety data are (in decreasing order): stomatitis, amenorrhoea, upper respiratory tract infections, hypercholesterolaemia, nasopharyngitis, menstruation irregular, acne, sinusitis, otitis media and pneumonia. The most frequent grade 3 4 adverse reactions (incidence 1%) were stomatitis, amenorrhoea, pneumonia, neutropenia, pyrexia, gastroenteritis viral and cellulitis.   |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/1343/ 201503 | Periodic Safety Update EU Single assessment - everolimus (indicated for astrocytoma (SEGA), renal angiomyolipoma, refractory seizures)                                                                                                                                                                                                                                                                                                                                        | 08/10/2015 | n/a        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| R/0033             | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                       | 21/05/2015 | 28/07/2015 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IB/0035            | B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                                                                                                                         | 01/07/2015 | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IB/0036/G          | This was an application for a group of variations. B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits                                                                                                                                                  | 29/05/2015 | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|           | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                             |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0030/G | This was an application for a group of variations. Update of SmPC section 5.2 to provide information regarding the effect of food on the pharmacokinetics of the Votubia dispersible tablets based on Study X2114. Further, the MAH took the opportunity to implement editorial changes in the SmPC. Update of SmPC section 4.5 to provide a recommendation to consider a washout period following discontinuation of concomitant moderate CYP3A4/PgP inhibitors and potent CYP3A4 inducers, and to align the corticosteroid inducer-classification with the approved Afinitor SmPC (pursuant to variation II-32) C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 26/02/2015 | 28/07/2015 | SmPC | In healthy subjects taking a single 9 mg dose (3 x 3 mg) of Votubia dispersible tablets in suspension, high fat meals reduced AUC by 11.7% and the peak blood concentration Cmax by 59.8%. Light fat meals reduced AUC by 29.5% and Cmax by 50.2%. Food, however, had no apparent effect on the post absorption phase concentration time profile 24 hours post- dose of either dosage form. |

<div style=\"page-break-after: always\"></div>

| IAIN/0032   | - Administrative change - Change in the name address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                 | 10/02/2015   | 28/07/2015   | SmPC, Labelling and PL   | A.1 and/or                                                                                                                                                                                                                                                                |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0613/G   | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The | 22/01/2015   | n/a          |                          | proposed manufacturer pharmaceutical group manufacturer B.I.a.2.a - Changes in the AS - Minor change of the AS B.I.a.2.a - Changes in the AS - Minor change of the AS B.I.a.3.a - Change in ranges) of AS or intermediate increase compared to size B.I.a.3.a - Change in |

<div style=\"page-break-after: always\"></div>

| size B.I.a.3.a - Change in batch ranges) of AS or intermediate increase compared to the size B.I.b.1.b - Change in the and/or limits of an AS, material/intermediate/reagent specification limits B.I.b.1.c - Change in the and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.c - Change in the and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.d - Change in the and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.c - Change in the and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.2.e - Change in test starting material/reagent/intermediate   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

| or addition) for the AS material/intermediate B.I.b.1.c - Change in and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.c - Change in and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.2.e - Change in starting material/reagent/intermediate changes to a test procedure or addition) for the AS material/intermediate B.I.b.1.c - Change in and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.c - Change in and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.2.e - Change in starting material/reagent/intermediate changes to a test procedure or addition) for the AS material/intermediate   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                            |            |            |      |                                                                                                                                                                                                                                                                                                                                                    |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUV/0025 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                               | 23/10/2014 | 16/12/2014 | SmPC | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUV/0025.                                                                                                                                                                                                                  |
| IA/0031/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 12/12/2014 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                    |
| II/0028   | Update of the efficacy data in section 5.1 of the SmPC (5-year analysis) based on the CSR for study CRAD001C2485, an open-label study of everolimus in patients with SEGA associated with TSC. The CSR is provided in accordance with Article 46 and is part of the post-authorisation measure ANX 016.                                                                                                                                              | 23/10/2014 | 16/12/2014 | SmPC | As part of the present application, the MAH has provided the final clinical study report (5-year analysis) for Study CRAD001C2485; a prospective, open-label, single-arm phase II study of everolimus in patients with SEGA. Twenty-eight evaluable patients with a confirmed diagnosis of TS and evidence of serial SEGA growth were recruited in |

<div style=\"page-break-after: always\"></div>

| C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   | data   |
|----------------------------------------------------------------------------------------------------------------|--------|

<div style=\"page-break-after: always\"></div>

| Of the 26 patients with a  30% reduction in primary SEGA volume at any time point per central review, two patients met the definition for progression (i.e., an increase from nadir of  25% to a value greater than baseline) at a later time point. Median duration from first response ( 30% reduction in primary SEGA volume) to progression or last radiological assessment was 56.74 months (range: 5.7 to 77.1 months) per central review (n=26). Similar results were obtained for local review. Of the 23 patients with a  50% reduction in primary SEGA   | Of the 26 patients with a  30% reduction in primary SEGA volume at any time point per central review, two patients met the definition for progression (i.e., an increase from nadir of  25% to a value greater than baseline) at a later time point. Median duration from first response ( 30% reduction in primary SEGA volume) to progression or last radiological assessment was 56.74 months (range: 5.7 to 77.1 months) per central review (n=26). Similar results were obtained for local review. Of the 23 patients with a  50% reduction in primary SEGA   | Of the 26 patients with a  30% reduction in primary SEGA volume at any time point per central review, two patients met the definition for progression (i.e., an increase from nadir of  25% to a value greater than baseline) at a later time point. Median duration from first response ( 30% reduction in primary SEGA volume) to progression or last radiological assessment was 56.74 months (range: 5.7 to 77.1 months) per central review (n=26). Similar results were obtained for local review. Of the 23 patients with a  50% reduction in primary SEGA   | Of the 26 patients with a  30% reduction in primary SEGA volume at any time point per central review, two patients met the definition for progression (i.e., an increase from nadir of  25% to a value greater than baseline) at a later time point. Median duration from first response ( 30% reduction in primary SEGA volume) to progression or last radiological assessment was 56.74 months (range: 5.7 to 77.1 months) per central review (n=26). Similar results were obtained for local review. Of the 23 patients with a  50% reduction in primary SEGA   | Of the 26 patients with a  30% reduction in primary SEGA volume at any time point per central review, two patients met the definition for progression (i.e., an increase from nadir of  25% to a value greater than baseline) at a later time point. Median duration from first response ( 30% reduction in primary SEGA volume) to progression or last radiological assessment was 56.74 months (range: 5.7 to 77.1 months) per central review (n=26). Similar results were obtained for local review. Of the 23 patients with a  50% reduction in primary SEGA   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| volume at any time point as per central review, one patient met the definition for progression (i.e., an increase from nadir of  25% to a value greater than baseline) at a later time point. Median duration from first response ( 50%                                                                                                                                                                                                                                                                                                                              | volume at any time point as per central review, one patient met the definition for progression (i.e., an increase from nadir of  25% to a value greater than baseline) at a later time point. Median duration from first response ( 50%                                                                                                                                                                                                                                                                                                                              | volume at any time point as per central review, one patient met the definition for progression (i.e., an increase from nadir of  25% to a value greater than baseline) at a later time point. Median duration from first response ( 50%                                                                                                                                                                                                                                                                                                                              | volume at any time point as per central review, one patient met the definition for progression (i.e., an increase from nadir of  25% to a value greater than baseline) at a later time point. Median duration from first response ( 50%                                                                                                                                                                                                                                                                                                                              | volume at any time point as per central review, one patient met the definition for progression (i.e., an increase from nadir of  25% to a value greater than baseline) at a later time point. Median duration from first response ( 50%                                                                                                                                                                                                                                                                                                                              |
| reduction in primary SEGA volume) to progression or last radiological assessment was 53.91 months (range: 0 to 77.1 months) per central review (n=23). Similar results were obtained for local review.                                                                                                                                                                                                                                                                                                                                                                 | reduction in primary SEGA volume) to progression or last radiological assessment was 53.91 months (range: 0 to 77.1 months) per central review (n=23). Similar results were obtained for local review.                                                                                                                                                                                                                                                                                                                                                                 | reduction in primary SEGA volume) to progression or last radiological assessment was 53.91 months (range: 0 to 77.1 months) per central review (n=23). Similar results were obtained for local review.                                                                                                                                                                                                                                                                                                                                                                 | reduction in primary SEGA volume) to progression or last radiological assessment was 53.91 months (range: 0 to 77.1 months) per central review (n=23). Similar results were obtained for local review.                                                                                                                                                                                                                                                                                                                                                                 | reduction in primary SEGA volume) to progression or last radiological assessment was 53.91 months (range: 0 to 77.1 months) per central review (n=23). Similar results were obtained for local review.                                                                                                                                                                                                                                                                                                                                                                 |
| Among the 28 patients included in this study, SEGA progressions were observed in a total of three patients (10.7%) as per central review and in seven patients                                                                                                                                                                                                                                                                                                                                                                                                         | Among the 28 patients included in this study, SEGA progressions were observed in a total of three patients (10.7%) as per central review and in seven patients                                                                                                                                                                                                                                                                                                                                                                                                         | Among the 28 patients included in this study, SEGA progressions were observed in a total of three patients (10.7%) as per central review and in seven patients                                                                                                                                                                                                                                                                                                                                                                                                         | Among the 28 patients included in this study, SEGA progressions were observed in a total of three patients (10.7%) as per central review and in seven patients                                                                                                                                                                                                                                                                                                                                                                                                         | Among the 28 patients included in this study, SEGA progressions were observed in a total of three patients (10.7%) as per central review and in seven patients                                                                                                                                                                                                                                                                                                                                                                                                         |
| (25.0%) as per local review. With reference to safety, total exposure to everolimus in patients with TSC-associated SEGA amounted to 145.5 patient- years. The median duration of exposure to everolimus was 67.8 months (range: 4.7 to 83.2 24 of the 28 patients (85.7%) were exposed to                                                                                                                                                                                                                                                                             | (25.0%) as per local review. With reference to safety, total exposure to everolimus in patients with TSC-associated SEGA amounted to 145.5 patient- years. The median duration of exposure to everolimus was 67.8 months (range: 4.7 to 83.2 24 of the 28 patients (85.7%) were exposed to                                                                                                                                                                                                                                                                             | (25.0%) as per local review. With reference to safety, total exposure to everolimus in patients with TSC-associated SEGA amounted to 145.5 patient- years. The median duration of exposure to everolimus was 67.8 months (range: 4.7 to 83.2 24 of the 28 patients (85.7%) were exposed to                                                                                                                                                                                                                                                                             | (25.0%) as per local review. With reference to safety, total exposure to everolimus in patients with TSC-associated SEGA amounted to 145.5 patient- years. The median duration of exposure to everolimus was 67.8 months (range: 4.7 to 83.2 24 of the 28 patients (85.7%) were exposed to                                                                                                                                                                                                                                                                             | (25.0%) as per local review. With reference to safety, total exposure to everolimus in patients with TSC-associated SEGA amounted to 145.5 patient- years. The median duration of exposure to everolimus was 67.8 months (range: 4.7 to 83.2 24 of the 28 patients (85.7%) were exposed to                                                                                                                                                                                                                                                                             |
| months).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | months).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | months).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | months).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | months).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| everolimus                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | everolimus                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | everolimus                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | everolimus                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | everolimus                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| treatment for a period of at least 57 months. The median                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | treatment for a period of at least 57 months. The median                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | treatment for a period of at least 57 months. The median                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | treatment for a period of at least 57 months. The median                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | treatment for a period of at least 57 months. The median                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| dose to                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | dose to                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | dose to                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | dose to                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | dose to                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 2.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 2.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 2.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 2.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 2.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | intensity was 5.04 mg/m2/day, with a range of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | intensity was 5.04 mg/m2/day, with a range of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | intensity was 5.04 mg/m2/day, with a range of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | intensity was 5.04 mg/m2/day, with a range of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| 10.5 mg/m2/day. The mean dose intensity was higher than the planned dosage (3 mg/m2/day). Dose interruptions, reductions and/or increases were required by all patients. A majority of patients had at least 2 dose reductions or interruptions (27 patients; 96.4%). Dose interruptions were primarily attributable to AEs (26 patients; 92.9%). Dose reductions were reported in 22 patients (78.6%), and were primarily due to protocol requirements (19 patients; 67.9%). Dose increases were primarily attributable to protocol requirements (28 patients; 100%). There were no AEs that led to study drug discontinuation. All patients experienced at least one AE suspected to be related to study drug. The most frequently reported AEs suspected to be related to study drug (in at least 30% patients), by PT were upper respiratory tract infection, cellulitis, gastroenteritis, stomatitis, mouth ulceration, sinusitis, otitis media and nasopharyngitis. Most AEs suspected to be related to study drug were considered by the Investigator to be grade 1 (mild) or grade 2 (moderate) in intensity. There were no grade 4 AEs suspected to be related to study drug. The most frequently reported grade 3 AEs by PT were cellulitis, pneumonia, sinusitis and stomatitis (2 patients each; 7.1%). The frequency of AEs suspected to be related to study drug reduced over the study period. One patient died during the study due to epilepsy. The Investigator did not suspect a relationship between the event and the study medication. Of the total number of AEs observed in the study, 32.1% AEs were considered SAEs, mostly of the SOC Infections   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                          |            |            |             | sixth year on everolimus - cellulitis and abscess in limb, which were grade 3 in severity. In conclusion, no new safety concerns have been raised with the final (5-year) analysis. The benefit / risk balance is not affected by this variation, and remains positive for the approved indications.                                                                                                                                                                                                                                                                                                                                                               |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0021 | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                            | 23/10/2014 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0027 | Update of the pooled safety data in section 4.8 of the SmPC in line with the revised Core Data Sheet following a review of the safety data from studies CRAD001M2301, CRAD001M2302 and CRAD001C2485. The Package Leaflet has been updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 25/09/2014 | 16/12/2014 | SmPC and PL | The MAH has submitted a report on longer-term observations in the TSC safety pool of 3 ongoing trials in TSC (C2485, M2301, and 2302) with a data lock point of 31 March 2014. With this method, the MAH has identified a new ADR (mild to moderate lymphoedema), and the MAH has also taken the opportunity to update section 4.8 of the SmPC in order to reflect safety according to an approximately 1-year longer exposure of TSC patients to Votubia in ongoing clinical trials. The changes to the SmPC and Package Leaflet are acceptable. The benefit / risk balance is not affected by this variation, and remains positive for the approved indications. |
| R/0024  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                  | 22/05/2014 | 18/07/2014 | SmPC and PL | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the annual renewal of the conditional MA for Votubia, subject to                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                          |            |            |             | the Specific Obligations and Conditions as laid down in Annex II to the Opinion.                                                                                                                                                                                                                                                                                                                                                                             |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0026   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                            | 03/07/2014 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0020   | Update of sections 4.2 and 5.2 of the SmPC further to the pharmacokinetic sub-study results from the pivotal trial CRAD001M2301 investigating the pharmacokinetics in the paediatric population (MEA 017). C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 26/06/2014 | 16/12/2014 | SmPC        | Limited data in patients <3 years of age (n=13) indicate that BSA normalised clearance is about two fold higher in patients with low BSA (BSA of 0.556 m2) than in adults. Therefore it is assumed that steady state could be reached earlier in patients <3 years of age Consequently, for patients <3 years of age, trough concentrations should be monitored at least 1 week after start of treatment or after any change in dose or pharmaceutical form. |
| PSUV/0022 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                   | 25/04/2014 | 19/06/2014 | SmPC and PL | Update of section 4.4 and 4.5 of the SmPC to add a warning on angioedema following the co-administration of everolimus and angiotensin converting enzyme inhibitors (ACEi). The Package leaflet was updated accordingly. Please refer to: Votubia-H-C-2311-PSUV-0022 EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation.                                                                       |
| IA/0023   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                            | 11/02/2014 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0019   | Update of Section 5.2 of the SmPC to clarify that the dose adjustments for hepatic impairment patients was based on results of two studies conducted in patients with impaired hepatic function relative to subjects with normal hepatic function.                                                                                                       | 21/11/2013 | 19/06/2014 | SmPC        | Following the assessment of the variation for Afinitor II-33, the section 5.2 of the SmPC was clarified that the dose adjustments for hepatic impairment patients was based on results of two clinical trials, X2102 and A2303.                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|          | The requested variation proposed amendments to the Summary of Product Characteristics. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |                                  |                                                                |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------|
| X/0008/G | This was an application for a group of variations. Extension of indication to include treatment of patients < 3 years of age with TSC who have SEGA. In addition, the SmPC was updated based on efficacy and safety data from the pivotal Study M2301 and longer-term follow-up from the Study C2485 for the SEGA paediatric population. A revised starting dose from 3 mg/m2 to 4.5 mg/m2 for patients with TSC who have SEGA has also been included. The SmPC was modified in sections 2, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.8, 5.1 and 5.2. The Package Leaflet and Labelling were updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. The requested group of variations proposed amendments to the SmP, Annex II, Labelling and Package Leaflet. Annex I_2.(d) Change or addition of a new pharmaceutical form C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or | 19/09/2013 | 15/11/2013 | SmPC, Annex II, Labelling and PL | Please refer to Scientific Discussion 'H-2311-VAR-X-08/G- en'. |

<div style=\"page-break-after: always\"></div>

| II/0016/G   | This was an application for a group of variations.   | 19/09/2013   | 15/11/2013   | SmPC and PL   | As requested by the CHMP, the MAH performed an analysis of the pooled safety data from the three studies in TSC-   |
|-------------|------------------------------------------------------|--------------|--------------|---------------|--------------------------------------------------------------------------------------------------------------------|
| N/0018      | Minor change in labelling or package leaflet not     | 07/08/2013   | 15/11/2013   | PL            |                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|           | connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                   |            |            |                        |                                             |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------|
| IA/0017/G | a group of variations. B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling        | 29/07/2013 | n/a        |                        | This was an application for down to 10-fold |
| R/0015    | Renewal of the marketing authorisation.                                                                                                                                                                                                                           | 25/04/2013 | 17/07/2013 | Annex II               |                                             |
|           | This was an application for a group of variations. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of | 25/01/2013 | n/a        |                        | IB/0014/G specification limits              |
| IB/0012   | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                               | 19/12/2012 | 15/07/2013 | SmPC, Labelling and PL |                                             |
| IG/0248   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                    | 17/12/2012 | n/a        |                        |                                             |
| IA/0011/G | This was an application for a group of variations.                                                                                                                                                                                                                | 07/11/2012 | n/a        |                        |                                             |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |             |                                                             |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------|
| II/0004   | Extension of indication to include Votubia for the treatment of 'adult patients with renal angiomyolipoma associated with tuberous sclerosis complex (TSC) who are at risk of complications (based on factors such as tumour size or presence of aneurysm, or presence of multiple or bilateral tumours) but who do not require immediate surgery. The evidence is based on analysis of change in sum of angiomyolipoma volume.'Consequently the sections 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 5.1, 5.2 and 6.6 of the SmPC were updated in order to include changes related to the indication. The Package Leaflet was updated accordingly. The requested variation proposed amendments to the SmPC and Package Leaflet. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 20/09/2012 | 31/10/2012 | SmPC and PL | Please refer to Scientific Discussion 'H-2311-VAR-II-04-en' |
| IG/0209/G | This was an application for a group of variations. C.I.9.b - Changes to an existing pharmacovigilance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 17/08/2012 | n/a        |             |                                                             |

<div style=\"page-break-after: always\"></div>

|           | system as described in the DDPS - Change in the contact details of the QPPV C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                                                                                                                                                                                   |            |            |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0005    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                              | 24/05/2012 | 26/07/2012 | SmPC and Annex II | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Votubia, subject to the Specific Obligations and Conditions as laid down in Annex II to the Opinion.                                             |
| IAIN/0006 | C.I.9.i - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) to a DDPS following the assessment of the same DDPS in relation to another medicinal product of the same MAH                                                                                                                                                                                                                                          | 29/06/2012 | n/a        |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0002   | Update of sections 4.2, 4.4, and 5.2 of the SmPC in order to update the safety information based on the results of study CRAD001X2102 which investigated the effect of everolimus in hepatically impaired patients (Child Pugh A-C) and dose adjustment according to grade. Section 4.2 was updated to include dosing recommendations for hepatically impaired patients, section 4.4 to advise on the precaution of the administration of Votubia in | 24/05/2012 | 28/06/2012 | SmPC              | The safety, tolerability and pharmacokinetics of Votubia were evaluated in a single oral dose study of everolimus in 34 adult subjects with impaired hepatic function relative to subjects with normal hepatic function. Compared to normal subjects, there was a 1.6-fold, 3.3-fold and 3.6-fold increase in exposure for subjects with mild (Child-Pugh A), moderate (Child-Pugh B) and severe (Child-Pugh C) hepatic impairment, respectively. Dose adjustment was recommended for adult patients with hepatic impairment. |

<div style=\"page-break-after: always\"></div>

|           | hepatically impaired patients, and section 5.2 to include the key results of the pharmacokinetic study of everolimus in subjects with impaired hepatic function. No changes have been proposed for the Package Leaflet. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                                                                                                          |            |            |             | However, Votubia was not recommended in adults with severe hepatic impairment and in children of less than 18 years of age with any grade of hepatic impairment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0001   | To update the product information for Votubia with Deep Vein Thrombosis (DVT) as an adverse drug reaction. Changes are as follows: to include deep vein thrombosis as an uncommon adverse drug reaction in section 4.8 of the Summary of Product Characteristics (SmPC) and as an uncommon side effect in Section 4 of the Package Leaflet (PL). C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 15/12/2011 | 06/02/2012 | SmPC and PL | From the MAH's clinical database, a total of 26 cases were identified with suspected relationship between everolimus administration and events of deep vein thrombosis reported in clinical studies and in post-marketing spontaneous reports. Of these, 16 cases originated from the renal cell carcinoma and pancreatic net tumour studies. The observed frequency of deep vein thrombosis events was between 0.5 and 1.6 %in the pooled databases for renal cell carcinoma and NET respectively. For post-marketing, a total of 3 cases of deep vein thrombosis were reported corresponding to 3400 patient years. The inclusion of deep vein thrombosis in the safety information was endorsed. The ADR has been added to the corresponding table in section 4.8 of the SmPC with the frequency of 'uncommon'. Section 4 of the Package Leaflet has been updated |
| IA/0003/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding                                                                                                                                                                                                                                                                                              | 16/12/2011 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|